Miglustat (Zavesca) is a glucosylceramide synthase inhibitor. It is indicated as monotherapy for adult patients with mild to moderate Type 1 Gaucher disease, and is only used in patients who cannot receive enzyme replacement therapy (e.g., due to allergy, hypersensitivity reaction, or poor venous access).

How to Purchase Miglustat (Zavesca)

1. Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or licensed drugstores in countries or regions where Miglustat is marketed.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

2. Purchase through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for the Use of Miglustat (Zavesca)

1. Pre-Treatment Evaluation Requirements

Neurological Examination: All patients must undergo a neurological function assessment at baseline and every 6 months during treatment.

Renal Function Testing: Dosage adjustment should be made based on creatinine clearance rate:

Mild renal impairment (50–70 mL/min/1.73 m²): The initial dose is 100 mg twice daily.

Moderate renal impairment (30–50 mL/min/1.73 m²): The initial dose is 100 mg once daily.

Severe renal impairment (<30 mL/min/1.73 m²): Use is not recommended.

2. Dosage Management Standards

Recommended Dosage: 100 mg orally, three times daily, at regular intervals.

Dosage Adjustment: If adverse reactions such as tremor or diarrhea occur, the dose can be reduced to 100 mg once or twice daily.

Missed Dose Handling: If a dose is missed, take the next dose at the originally scheduled time; do not make up for the missed dose.

3. Contraindications and Drug Interactions

Contraindications: There are no absolute contraindications, but the drug is contraindicated in patients with severe renal impairment.

Drug Interactions: Concomitant use with imiglucerase may increase the clearance rate of imiglucerase, so caution is required when using them together.

4. Management for Special Populations

Pregnant Women: Based on animal data, Miglustat may cause fetal harm. Effective contraception is required during treatment.

Lactating Women: Breastfeeding is not recommended during treatment and after the last dose.

Methods to Identify the Authenticity of Miglustat (Zavesca)

1. Verification of Appearance Characteristics

Capsule Specification: 100 mg miglustat, white opaque hard gelatin capsules. The cap is printed with "OGT918" in black, and the body is printed with "100" in black.

2. Confirmation of Packaging Information

Authentic products use child-resistant blister packaging. Each box contains 90 capsules (6 blister cards, with 15 capsules per card).

The label must fully include the drug name, batch number, expiration date, and manufacturer information.